Transcript for By the Numbers: Race for the COVID-19 vaccine
And now back to the promising vaccine is is giving us hope as Kobe case is continued to surge AstraZeneca. Is now the third drugmaker to claim its vaccine is highly effective at fighting the virus here's a look at the vaccine raised by the numbers up to 90%. That's how effective AstraZeneca an Oxford University say they're vaccine is based on an interim analysis of phase three trials involving more than 24000. Volunteers in the UK in Brazil none of the vaccinated trial participants needed hospitalization for company in nineteen on the expect to produce and distribute. Three billion doses in 20/20 one on a rolling basis pending regulatory approval. And because AstraZeneca has vaccine can last at least six months in a normal refrigerator distribution could be easier than other vaccines and also cost less than four dollars a doze. Meanwhile Pfizer and buying on tax say that there vaccine is up to 95%. Effective. And with FDA approval rollout could begin as soon as December 11. Pfizer expects to produce up to fifty million doses in twenty Tony enough to one point three billion doses globally by the end of 20/20 one. That vaccine however requires ultra cold storage after several days and finally drugmaker Madeira says its vaccine is 94 point 5% effective based on preliminary analysis. They could have twenty million doses by the end of the year.
This transcript has been automatically generated and may not be 100% accurate.